Please use this identifier to cite or link to this item: https://doi.org/10.1160/TH12-01-0039
DC FieldValue
dc.titleTranslational platelet research in patients with coronary artery disease: What are the major knowledge gaps?
dc.contributor.authorGurbel, P.A.
dc.contributor.authorRoe, M.T.
dc.contributor.authorJakubowski, J.A.
dc.contributor.authorShah, S.
dc.contributor.authorErlinge, D.
dc.contributor.authorGoodman, S.G.
dc.contributor.authorHuber, K.
dc.contributor.authorChan, M.Y.
dc.contributor.authorCornel, J.H.
dc.contributor.authorTantry, U.S.
dc.contributor.authorMagnus Ohman, E.
dc.date.accessioned2016-09-06T08:43:14Z
dc.date.available2016-09-06T08:43:14Z
dc.date.issued2012-07
dc.identifier.citationGurbel, P.A., Roe, M.T., Jakubowski, J.A., Shah, S., Erlinge, D., Goodman, S.G., Huber, K., Chan, M.Y., Cornel, J.H., Tantry, U.S., Magnus Ohman, E. (2012-07). Translational platelet research in patients with coronary artery disease: What are the major knowledge gaps?. Thrombosis and Haemostasis 108 (1) : 12-20. ScholarBank@NUS Repository. https://doi.org/10.1160/TH12-01-0039
dc.identifier.issn03406245
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/126938
dc.description.abstractTranslational platelet function investigations performed in the percutaneous coronary intervention (PCI)-treated population receiving clopidogrel have identified high platelet reactivity to ADP (HPR) as a major risk factor for both acute as well as long-term ischaemic event occurrence, including stent thrombosis. Recent studies have highlighted the relation of single nucleotide polymorphisms of genes involved in clopidogrel absorption and metabolism to reduced pharmacokinetic and pharmacodynamic responses to clopidogrel. CYP 2C19 loss-of-function (LoF) allele carriage has been associated with increased thrombotic risk in the PCI population. However, there is no information regarding the utility of platelet function testing to predict outcomes in patients with stable coronary artery disease and in medically managed patients with acute coronary syndromes. Additionally, few studies have included longitudinal assessment of platelet function to assess a potential timedependent relation to ischaemic event occurrence and no phase-III antiplatelet-therapy trial has included a large enough platelet function sub-study to examine the relation between on-treatment platelet reactivity, bleeding, and ischaemic event occurrence. Therefore, futher studies are needed to delineate the role of platelet function testing across the spectrum of symptomatic coronary artery disease. © Schattauer 2012.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1160/TH12-01-0039
dc.sourceScopus
dc.subjectADP receptors
dc.subjectAntiplatelet drugs
dc.subjectClinical trials
dc.subjectCoronary syndrome
dc.subjectPlatelet pharmacology
dc.typeReview
dc.contributor.departmentMEDICINE
dc.description.doi10.1160/TH12-01-0039
dc.description.sourcetitleThrombosis and Haemostasis
dc.description.volume108
dc.description.issue1
dc.description.page12-20
dc.description.codenTHHAD
dc.identifier.isiut000306538400006
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

7
checked on Nov 29, 2021

WEB OF SCIENCETM
Citations

6
checked on Nov 22, 2021

Page view(s)

74
checked on Nov 18, 2021

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.